SitesBLAST

D54 (≠ E23) mutation to A: Loss of transport activity.; mutation to E: Retains 50% of its transport activity.
D57 (= D26) mutation to A: Loss of transport activity.; mutation to E: Retains 50% of its transport activity.
R103 (= R79) mutation to A: Loss of transport activity.

Sites not aligning to the query:

309 W→V: Loss of transport activity.
312 D→A: Loss of transport activity.
313 R→A: Loss of transport activity.
317 mutation I->H,Y: Loss of transport activity.
386 R→A: Loss of transport activity.

Q63089 Solute carrier family 22 member 1; Organic cation transporter 1; rOCT1 from Rattus norvegicus (Rat) (see 4 papers)
30% identity, 38% coverage: 61:225/436 of query aligns to 158:301/556 of Q63089

query
sites
Q63089

V

L

G

G

F

F

A

-

R

-

P

-

L

L

G

G

G

S

I

L

V

V

F

V

G

G

H

Y

I

I

G

A

D

D

R

R

I

F

G

G

R

R

K

K

K

L

S
x
C

L

L

I

L

I

V

T

T

L

T

L

L

M

V

M

T

G

S

V

V

V

S

T

G

V

V

C

L

I

T

G

A

L

V

L

A

P

P

T

D

Y

Y

A

T

Q

S

I

-

G

-

A

-

P

-

V

-

L

-

L

M

I

L

L

L

L

F

R

R

I

L

V

L

Q

Q

G

G

I
x
M

A
x
V

V
x
S

G
x
K

G
|
G

E
x
S

W
|
W

G
x
V

G
x
S

A
x
G

V
x
Y

L
x
T

M
x
L

A
x
I

G
x
T

E
|
E

H
x
F

A
x
V

P

G

K

S

G

G

R

Y

R

R

N

R

F

T

A

A

S

I

F

L

A

Y

Q

Q

L

M

G

A

S

F

P

T

A

V

G

G

L

L

I

V

-

G

L

L

S

A

L

G

L

V

A

A

F

Y

S

A

A

-

V

-

T

-

R

-

L

I

P

P

E

D

E

-

D

-

L

-

M

-

S

-

W

-

G

-

W

W

R

R

L

W

P

L

F

Q

L

L

A

A

S

V

S

S

L

L

L

P

L

T

L

F

V

L

G

F

L

L

A

L

I

Y

R

Y

L

W

G

F

V

V

N

P

E

E

S
|
S

P

P

E

R

F

W

L

L

A

L

S
|
S

R

Q

E

K

L

R

A
x
T

S

T

K

R

N

A

K

V

R

R

C179 (≠ S85) mutation to A: Choline affinity is increased fourfold by MMTS; when associated with A-26; A-155; S-322; A-358; A-418; S-437; A-470 and A-474.
M212 (≠ I126) mutation to L: No change in TEA and MPP(+) uptake.
V213 (≠ A127) mutation to G: Decreased TEA uptake. No change in MPP(+) uptake.
S214 (≠ V128) mutation to G: Decreased TEA and MPP(+) uptake.
K215 (≠ G129) mutation to Q: Loss of TEA and MPP(+) uptake activity.; mutation to R: Loss of TEA and MPP(+) uptake activity.
G216 (= G130) mutation to A: Decreased TEA and MPP(+) uptake.
S217 (≠ E131) mutation to G: No change in TEA and MPP(+) uptake.
W218 (= W132) mutation to F: Decreased guanidine, histamine, serotonin and TEA uptake. No change in MPP(+) uptake. No change in TEA and MPP(+) affinity. Decreased TEA Vmax. No change in MPP(+) Vmax.; mutation to L: Decreased guanidine, histamine, serotonin, TEA and MPP(+) uptake. Decreased TEA affinity. No change in MPP(+) affinity. Decreased TEA and MPP(+) Vmax.; mutation to Y: Decreased guanidine, histamine, serotonin and TEA uptake. No change in MPP(+) uptake. Increased TEA and MPP(+) affinity. Decreased TEA and MPP(+) Vmax.
V219 (≠ G133) mutation to L: No change in TEA and MPP(+) uptake.
S220 (≠ G134) mutation to I: Decreased TEA and MPP(+) uptake.
G221 (≠ A135) mutation to A: Decreased TEA and MPP(+) uptake.
Y222 (≠ V136) mutation to F: No change in guanidine, histamine, serotonin, TEA and MPP(+) uptake. Increased TEA affinity. No change in MPP(+) affinity. Decreased TEA Vmax. No change in MPP(+) Vmax.; mutation to L: Decreased guanidine, serotonin, TEA and MPP(+) uptake. No change in histamine uptake. Increased TEA and MPP(+) affinity. Decreased TEA and MPP(+) Vmax.
T223 (≠ L137) mutation to I: Decreased TEA uptake. No change in MPP(+) uptake.
L224 (≠ M138) mutation to V: Decreased TEA and MPP(+) uptake.
I225 (≠ A139) mutation to G: No change in TEA and MPP(+) uptake.
T226 (≠ G140) mutation to A: Decreased TEA uptake. No change in MPP(+) uptake.
E227 (= E141) mutation to D: Loss of TEA and MPP(+) uptake activity.; mutation to Q: Loss of TEA and MPP(+) uptake activity.
F228 (≠ H142) mutation to I: No change in TEA and MPP(+) uptake.
V229 (≠ A143) mutation to A: Decreased TEA and MPP(+) uptake.; mutation to L: Loss of TEA and MPP(+) uptake activity.
S286 (= S210) mutation to A: No effect of PKC-induced stimulation on ASP uptake. No effect of PKC-induced stimulation on ASP uptake; when associated with A-292; A-296; A-328 and A-550. No effect of PKA activation on ASP uptake. No effect of PKA activation on ASP uptake; when associated with A-292; A-296; A-328 and A-550. Significant reduction of ASP uptake by p56(lck) tyrosine kinase-induced inhibition. Significant reduction of ASP uptake by p56(lck) tyrosine kinase-induced inhibition; when associated with A-292; A-296; A-328 and A-550. No significant effect on trafficking from intracellular pools to the cell membrane; when associated with A-292; A-296; A-328 and A-550. suppresses phosphorylation by PKC; when associated with A-292; A-296; A-328 and A-550.
S292 (= S216) mutation to A: No effect of PKC-induced stimulation on ASP uptake. No effect of PKC-induced stimulation on ASP uptake; when associated with A-286; A-296; A-328 and A-550. No effect of PKA activation on ASP uptake. No effect of PKA activation on ASP uptake; when associated with A-286; A-296; A-328 and A-550. Significant reduction of ASP uptake by p56(lck) tyrosine kinase-induced inhibition. Significant reduction of ASP uptake by p56(lck) tyrosine kinase-induced inhibition; when associated with A-286; A-296; A-328 and A-550. No significant effect on trafficking from intracellular pools to the cell membrane; when associated with A-286; A-296; A-328 and A-550. suppresses phosphorylation by PKC; when associated with A-286; A-296; A-328 and A-550.
T296 (≠ A220) mutation to A: No effect of PKC-induced stimulation on ASP uptake. No effect of PKC-induced stimulation on ASP uptake; when associated with A-286; A-292; A-328; A-550. Significant increase of the ASP uptake by PKA activation. No effect of PKA activation on ASP uptake; when associated with A-286; A-292; A-328; A-550. Significant reduction of ASP uptake by p56(lck) tyrosine kinase-induced inhibition. Significant reduction of ASP uptake by p56(lck) tyrosine kinase-induced inhibition; when associated with A-286; A-292; A-328; A-550. No significant effect on trafficking from intracellular pools to the cell membrane; when associated with A-286; A-292; A-328 and A-550. suppresses phosphorylation by PKC; when associated with A-286; A-292; A-328 and A-550.

Sites not aligning to the query:

26 C→A: Choline affinity is increased fourfold by MMTS; when associated with A-155; A-179; S-322; A-358; A-418; S-437; A-470 and A-474.
155 C→A: Choline affinity is increased fourfold by MMTS; when associated with A-26; A-179; S-322; A-358; A-418; S-437; A-470 and A-474.
322 C→S: Reduces the activation by MMTS. Abolishes the activation by MMTs; when associated with M-451. Choline affinity is increased fivefold by MMTS. Choline affinity is increased fourfold by MMTS; when associated with A-26; A-155; A-179; A-358; A-418; S-437; A-470 and A-474. Choline affinity is increased four- to fivefold; when associated with M-451.
328 S→A: No effect of PKC-induced stimulation on ASP uptake. No effect of PKC-induced stimulation on ASP uptake; when associated with A-286; A-292; A-296 and A-550. No effect of PKA activation on ASP uptake. No effect of PKA activation on ASP uptake; when associated with A-286; A-292; A-296 and A-550. Significant reduction of ASP uptake by p56(lck) tyrosine kinase-induced inhibition. Significant reduction of ASP uptake by p56(lck) tyrosine kinase-induced inhibition; when associated with A-286; A-292; A-296; A-550. No significant effect on trafficking from intracellular pools to the cell membrane; when associated with A-286; A-292; A-296 and A-550. suppresses phosphorylation by PKC; when associated with A-286; A-292; A-296 and A-550.
358 C→A: Choline affinity is increased fourfold by MMTS; when associated with A-26; A-155; A-179; S-322; A-418; S-437; A-470 and A-474.
418 C→A: Choline affinity is increased fourfold by MMTS; when associated with A-26; A-155; A-179; S-322; A-358; S-437; A-470 and A-474.
437 C→S: Choline affinity is increased fourfold by MMTS; when associated with A-26; A-155; A-179; S-322; A-358; A-418; A-470 and A-474.
451 C→M: Reduces the activation by MMTS. Abolishes the activation by MMTs; when associated with S-322. Abolishes the effect of MMTs on choline-induced currents. Choline affinity is not influenced by MMTS. Choline affinity is increased four- to fivefold; when associated with S-322.
470 C→A: Choline affinity is increased fourfold by MMTS; when associated with A-26; A-155; A-179; S-322; A-358; A-418; A-437 and A-474.
474 C→A: Choline affinity is increased fourfold by MMTS; when associated with A-26; A-155; A-179; S-322; A-358; A-418; A-437 and A-470.
475 D→E: Decreased MPP(+) uptake, no change in MPP(+) affinity. Decreased NMN uptake, increased NMN affinity. Decreased choline uptake, increased choline affinity.; D→N: Decreased MPP(+) uptake.; D→R: Decreased MPP(+) uptake.
550 T→A: No effect of PKC-induced stimulation on ASP uptake. No effect of PKC-induced stimulation on ASP uptake; when associated with A-286; A-292; A-296; A-328. Significant increase of the ASP uptake by PKA activation. No effect of PKA activation on ASP uptake; when associated with A-286; A-292; A-296 and A-328. Significant reduction of ASP uptake by p56(lck) tyrosine kinase-induced inhibition. Significant reduction of ASP uptake by p56(lck) tyrosine kinase-induced inhibition; when associated with A-286; A-292; A-296; A-328. No significant effect on trafficking from intracellular pools to the cell membrane; when associated with A-286; A-292; A-296 and A-328. suppresses phosphorylation by PKC; when associated with A-286; A-292; A-296 and A-328.

8et8A Cryo-em structure of the organic cation transporter 1 in complex with verapamil (see paper)
32% identity, 39% coverage: 61:229/436 of query aligns to 156:297/532 of 8et8A

query
sites
8et8A

V

V

G

G

F

F

A

-

R

-

P

-

L

L

G

G

G

S

I

L

V

G

F

V

G

G

H

Y

I

I

G

A

D

D

R

R

I

F

G

G

R

R

K

K

K

L

S

C

L

L

I

L

I

A

T

T

L

T

L

L

M

I

M

S

G

A

V

V

V

S

T

G

V

V

C

L

I

M

G

A

L

V

L

A

P

P

T

D

Y

Y

A

T

Q

S

I

-

G

-

A

-

P

-

V

-

L

-

L

M

I

L

L

L

L

F

R

R

I

L

V

L

Q

Q

G

G

I

L

A

V

V

S

G
x
K

G

G

E

S

W
|
W

G

M

G

S

A

G

V

Y

L

T

M

L

A

I

G

T

E

E

H

F

A

V

P

G

K

S

G

G

R

Y

R

R

N

R

F

T

F

V

A

A

S

I

F

L

A

Y

Q
|
Q

L

M

G

A

S

F

P

T

A

V

G

G

L

L

I

V

-

L

L

L

S

S

L

G

L

V

A

A

F

Y

S

A

A

-

V

-

T

-

R

-

L

I

P

P

E

H

E

-

D

-

L

-

M

-

S

-

W

-

G

-

W

W

R

R

L

W

P

L

F

Q

L

L

A

A

S

V

S

S

L

L

L

P

L

T

L

F

V

L

G

F

L

L

A

L

I

Y

R

Y

L

W

G

C

V

V

N

P

E

E

S

S

P

P

E

R

F

W

L

L

A

L

S

S

R

Q

E

-

L

-

A

-

S

-

K

-

N

-

K

K

R

R

K

N

E

T

Q

Q

A

A

binding (2S)-2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile: K213 (≠ G129), W216 (= W132), Q240 (= Q156)

Sites not aligning to the query:

binding (2S)-2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile: 31, 35, 353, 360, 378, 381, 385, 449, 469

8et7A Cryo-em structure of the organic cation transporter 1 in complex with diphenhydramine (see paper)
32% identity, 39% coverage: 61:229/436 of query aligns to 156:297/532 of 8et7A

query
sites
8et7A

V

V

G

G

F

F

A

-

R

-

P

-

L

L

G

G

G

S

I

L

V

G

F

V

G

G

H

Y

I

I

G

A

D

D

R

R

I

F

G

G

R

R

K

K

K

L

S

C

L

L

I

L

I

A

T

T

L

T

L

L

M

I

M

S

G

A

V

V

V

S

T

G

V

V

C

L

I

M

G

A

L

V

L

A

P

P

T

D

Y

Y

A

T

Q

S

I

-

G

-

A

-

P

-

V

-

L

-

L

M

I

L

L

L

L

F

R

R

I

L

V

L

Q

Q

G

G

I

L

A

V

V

S

G

K

G

G

E

S

W

W

G

M

G

S

A

G

V

Y

L

T

M

L

A

I

G

T

E

E

H

F

A

V

P

G

K

S

G

G

R

Y

R

R

N

R

F

T

F

V

A

A

S

I

F

L

A

Y

Q

Q

L

M

G

A

S

F

P

T

A

V

G

G

L

L

I

V

-

L

L

L

S

S

L

G

L

V

A

A

F

Y

S

A

A

-

V

-

T

-

R

-

L

I

P

P

E

H

E

-

D

-

L

-

M

-

S

-

W

-

G

-

W

W

R

R

L

W

P

L

F

Q

L

L

A

A

S

V

S

S

L

L

L

P

L

T

L

F

V

L

G

F

L

L

A

L

I

Y

R

Y

L

W

G

C

V

V

N

P

E

E

S

S

P

P

E

R

F

W

L

L

A

L

S

S

R

Q

E

-

L

-

A

-

S

-

K

-

N

-

K

K

R

R

K

N

E

T

Q

Q

A

A

Sites not aligning to the query:

binding n-[2-(benzhydryloxy)ethyl]-n,n-dimethylamine: 35, 385, 445

O08966 Solute carrier family 22 member 1; Organic cation transporter 1; mOCT1 from Mus musculus (Mouse) (see paper)
30% identity, 38% coverage: 61:225/436 of query aligns to 158:301/556 of O08966

query
sites
O08966

V

L

G

G

F

F

A

-

R

-

P

-

L

L

G

G

G

S

I

L

V

V

F

V

G

G

H

Y

I

I

G

A

D

D

R

R

I

F

G

G

R

R

K

K

K

L

S

C

L

L

I

L

I

V

T

T

L

T

L

L

M

V

M

T

G

S

V

L

V

S

T

G

V

V

C

L

I

T

G

A

L

V

L

A

P

P

T

D

Y

Y

A

T

Q

S

I

-

G

-

A

-

P

-

V

-

L

-

L

M

I

L

L

L

L

F

R

R

I

L

V

L

Q

Q

G

G

I

M

A

V

V

S

G

K

G

G

E

S

W

W

G

V

G

S

A

G

V

Y

L

T

M

L

A

I

G

T

E

E

H

F

A

V

P

G

K

S

G

G

R

Y

R

R

N

R

F

T

A

A

S

I

F

L

A

Y

Q

Q

L

V

G

A

S

F

P

T

A

V

G

G

L

L

I

V

-

G

L

L

S

A

L

G

L

V

A

A

F

Y

S

A

A

-

V

-

T

-

R

-

L

I

P

P

E

D

E

-

D

-

L

-

M

-

S

-

W

-

G

-

W

W

R

R

L

W

P

L

F

Q

L

L

A

A

S

V

S

S

L

L

L

P

L

T

L

F

V

L

G

F

L

L

A

L

I

Y

R

Y

L

W

G

F

V

V

N

P

E

E

S

S

P

P

E

R

F

W

L

L

A

L

S

S

R

Q

E

K

L

R

A

T

S

T

K

Q

N

A

K

V

R

R

Sites not aligning to the query:

32 L→F: Increased trospium uptake. Increased trospium affinity. No change in fenoterol uptake.
36 Y→C: Decreased fenoterol uptake. Decreased fenoterol affinity. No change in trospium uptake. No change in terbutaline affinity.

O15245 Solute carrier family 22 member 1; Organic cation transporter 1; hOCT1 from Homo sapiens (Human) (see 10 papers)
29% identity, 41% coverage: 56:233/436 of query aligns to 161:303/554 of O15245

query
sites
O15245

F

F

G

G

T

S

F

L

A

G

V

V

G

G

F

Y

F

F

A

A

R

-

P

-

L

-

G

-

I

-

V

-

F

-

G

-

H

-

I

-

G

-

D

D

R

R

I

F

G

G

R

R

K

K

K

L

S

C

L

L

I

L

I

G

T

T

L

V

L

L

M

V

M

N

G

A

V

V

V
x
S

T

G

V

V

C

L

I

M

G

A

L

F

L

S

P

P

T

N

Y

Y

A

M

Q

S

I

-

G

-

A

-

P

-

V

-

L

-

L

M

I

L

L

L

L

F

R

R

I

L

V

L

Q

Q

G

G

I

L

A

V

V

S

G

K

G

G

E

N

W

W

G

M

G

A

A
x
G

V

Y

L

T

M

L

A

I

G

T

E

E

H

F

A

V

P

G

K

S

G

G

R

S

R

R

N

R

F

T

F

V

A

A

S

I

F

M

A
x
Y

Q

Q

L

M

G

A

S

F

P

T

A

V

G

G

L

L

I

V

-

A

L

L

S

T

L

G

L

L

A

A

F

Y

S

A

A

-

V

-

T

-

R

-

L

L

P

P

E

H

E

-

D

-

L

-

M

-

S

-

W

-

G

-

W

W

R

R

L

W

P

L

F

Q

L

L

A

A

S

V

S

S

L

L

L

P

L

T

L

F

V

L

G

F

L

L

A

L

I

Y

R

Y

L

W

G

C

V

V

N
x
P

E

E

S

S

P

P

E

-

F

-

L

-

A

-

S

-

R
|
R

E

W

L

L

A

L

S

S

K

Q

N

K

K

R

R

N

K

T

E

E

Q

A

A

I

P

K

V

I

M

M

E

D

S189 (≠ V96) to L: no changes in MPP(+) uptake; dbSNP:rs34104736
G220 (≠ A135) to V: affects transporter activity; reduction of MPP(+) uptake when associated with V-408; dbSNP:rs36103319
Y240 (≠ A155) mutation to F: Decreased TEA uptake.
P283 (≠ N208) to L: in dbSNP:rs4646277; mutation to A: Decreased TEA uptake.
R287 (= R217) to G: in dbSNP:rs4646278

Sites not aligning to the query:

14 S → F: exclusively found in the African American population; increased MPP(+) uptake when associated with V-408; dbSNP:rs34447885
24 I→L: No change in fenoterol uptake. No change in trospium uptake. No change in terbutaline uptake.
28 L→I: No change in fenoterol uptake. No change in trospium uptake. No change in terbutaline uptake.
31 A→S: No change in fenoterol uptake. No change in trospium uptake. No change in terbutaline uptake.
32 F→L: No change in fenoterol uptake. Decreased trospium uptake. Decreased trospium affinity.
36 C→Y: Increased fenoterol uptake. Increased fenoterol affinity. No change in trospium uptake. No change in terbutaline uptake. No change in terbutaline affinity.
41 F → L: in dbSNP:rs2297373
61 R → C: affects transporter activity; reduction of MPP(+) uptake; reduction of serum O-isobutanoyl-(R)-carnitine levels; reduction of MPP(+) uptake when associated with V-408; dbSNP:rs12208357
85 L → F: no changes in MPP(+) uptake; when associated with V-408; dbSNP:rs35546288
88 C → R: affects transporter activity; reduction of MPP(+), serotonin and TEA uptake; dbSNP:rs55918055
160 L → F: no changes in both MPP(+) and TEA uptake; abolishes MPP(+) uptake when associated with S-401; largely localized to the plasma membrane; dbSNP:rs683369
341 P → L: affects transporter activity; reduction of TEA uptake; reduction o MPP(+) uptake when associated with V-408; largely localized to the plasma membrane; dbSNP:rs2282143
342 R → H: no changes in MPP(+) uptake when associated with V-408; dbSNP:rs34205214
361 Y→F: Decreased TEA uptake.
376 Y→F: Decreased TEA uptake.
401 G → S: affects transporter activity; reduction of MPP(+), serotonin and TEA uptake; no MPP(+) uptake when associated with L-160; dbSNP:rs34130495
408 M → V: does not affect transporter activity; no changes in MPP(+) uptake when associated with F-14; no changes in MPP(+) uptake when associated with F-85; no changes in MPP(+) uptake when associated with L-189; no changes in MPP(+) uptake when associated with H-342; no changes in MPP(+) uptake when associated with M-420 del; no changes in MPP(+) uptake when associated with I-440; no changes in MPP(+) uptake when associated with I-461; no changes in MPP(+) uptake when associated with M-488; reduction of MPP uptake when associated with C-61; no MPP(+) uptake when associated with V-220; reduction of MPP(+) uptake when associated with L-341; no MPP(+) uptake when associated with S-401; no MPP(+) uptake when associated with R-465; dbSNP:rs628031
420 natural variant: Missing (reduction of serum O-isobutanoyl-(R)-carnitine levels; no change in MPP(+) uptake; no changes in MPP(+) uptake when associated with V-408; dbSNP:rs72552763)
440 M → I: in dbSNP:rs35956182
461 V → I: no changes in MPP(+) uptake when associated with V-408; dbSNP:rs34295611
465 G → R: reduction of the localization to the basolateral membrane; no MPP(+) uptake when associated with V-408; dbSNP:rs34059508; G→A: No changes in MPP(+) uptake.
488 R → M: no changes in MPP(+) uptake when associated with V-408; dbSNP:rs35270274

P36035 Carboxylic acid transporter protein homolog from Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast) (see paper)
26% identity, 36% coverage: 64:219/436 of query aligns to 186:331/616 of P36035

query
sites
P36035

F

F

A

V

R

R

P

S

L

A

G

G

G

A

I

V

V

I

F

F

G

G

H

L

I

W

G

T

D

D

R

K

I

S

G

S

R

R

K

K

K

W

S

P

L

Y

I

I

I

T

T

C

L

L

L

F

M

L

M

F

G

V

V

I

V

A

T

Q

V

L

C

C

I

T

G

P

L

W

L

C

P

D

T

T

Y

Y

A

E

Q

K

I

-

G

-

A

-

P

-

V

-

L

-

L

F

I

L

L

G

L

V

R

R

I

W

V

I

Q

T

G

G

I

I

A

A

V

M

G

G

E

I

W

Y

G

G

G

C

A

A

V

S

L

A

M

T

A

A

G

I

E

E

H

D

A

A

P

P

K

V

G

K

R

A

R

R

N

S

F

F

F

L

A

S

S

G

F

L

A

F

Q

F

L

S

G

A

S

Y

P

A

A

M

G

G

L

F

I

I

L

F

S

A

L

I

A

F

F

Y

S

R

A

A

V

F

T

G

R

Y

L

F

P

R

E

D

D

-

L

-

M

-

S

-

W

-

G

G

W

W

R

K

L

I

P

L

F

F

L

W

A

F

S

S

S

I

L

F

L

L

L

P

L

I

V

L

G

L

L

I

A

F

I

W

R

R

L

L

G

L

V

W

N

P

E

E

S

T

P

K

E

Y

F

F

-

T

-

K

-

V

L

L

A

K

S

A

R

R

E

K

L

L

Sites not aligning to the query:

1 modified: Initiator methionine, Removed
9 modified: Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)
338 modified: Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)

O15244 Solute carrier family 22 member 2; Organic cation transporter 2; hOCT2 from Homo sapiens (Human) (see 8 papers)
28% identity, 38% coverage: 61:227/436 of query aligns to 158:298/555 of O15244

query
sites
O15244

V

V

G

G

F

F

A

-

R

-

P

-

L

I

G

G

G

S

I
x
M

V

S

F

I

G

G

H
x
Y

I

I

G

A

D

D

R

R

I

F

G

G

R

R

K

K

K

L

S

C

L

L

I

L

I

T

T

T

L

V

L

L

M

I

M

N

G

A

V

A

T

G

V

V

C

L

I

M

G

A

L

I

L

S

P

P

T

T

Y

Y

A
x
T

Q

-

I

-

G

-

A

-

P

-

V

-

L

W

L

M

I

L

L

I

L

F

R

R

I

L

V

I

Q

Q

G

G

I

L

A

V

V

S

G

K

G

A

E

G

W

W

G

L

G

I

A

G

V

Y

L

I

M

L

A

I

G

T

E

E

H

F

A

V

P

G

K

R

G

R

R

Y

R

R

N

R

F

T

F

V

A

G

S

I

F

F

A
x
Y

Q

Q

L

V

G

A

S

Y

P

T

A

V

G

G

-

L

L

L

I

V

L

L

S

A

L

G

L

V

A

A

F
x
Y

S

A

A

-

V

-

T

-

R

-

L

L

P

P

E

H

E

-

D

-

L

-

M

-

S

-

W

-

G

-

W

W

R

R

L

W

P

L

F

Q

L

F

A

T

S

V

S
|
S

L

L

L

P

L

N

L

F

V

F

G

F

L

L

A

L

I
x
Y

R
x
Y

L

W

G

C

V

I

N
x
P

E
|
E

S
|
S

P
|
P

E

-

F

-

L

-

A

-

S

-

R
|
R

E

W

L

L

A

I

S

S

K

Q

N

N

K

K

R

N

K

A

E

E

M165 (≠ I71) to I: lower Vmax for MPP(+) transport; no change in transport efficiency (Vmax/Km) and clearance of cyclo(his-pro) and salsolinol; dbSNP:rs8177507
Y169 (≠ H75) mutation to F: No change in TEA uptake.
T201 (≠ A107) to M: in dbSNP:rs145450955
Y241 (≠ A155) mutation to F: Slight decrease in TEA uptake. No change in tyrosine phosphorylation. Strong decrease in TEA uptake; when associated with F-362. Strong decrease in TEA and metformin uptake and YES1-mediated tyrosine phosphorylation; when associated with F-362 and F-377.
Y257 (≠ F170) mutation to F: No change in TEA uptake.
S270 (= S194) to A: decreased Ki value for TBA inhibition of MPP(+); no change in transport efficiency (Vmax/Km) and clearance of cyclo(his-pro) and salsolinol; dbSNP:rs316019
Y279 (≠ I203) mutation to F: No change in TEA uptake.
Y280 (≠ R204) mutation to F: No change in TEA uptake.
P284 (≠ N208) mutation to A: Decreased TEA and metformin uptake. Decreased tyrosine phosphorylation.
PESP-----R 284:288 (≠ NESPEFLASR 208:217) Proline-rich sequence
S286 (= S210) mutation to A: No change in TEA and metformin uptake. No change in tyrosine phosphorylation.
P287 (= P211) mutation to A: Decreased TEA and metformin uptake. Decreased tyrosine phosphorylation.

Sites not aligning to the query:

54 P → S: in dbSNP:rs8177504
73 Y→F: No change in TEA uptake.
92 Y→F: No change in TEA uptake.
128 Y→F: No change in TEA uptake.
362 Y→F: Decreased TEA uptake and YES1-mediated tyrosine phosphorylation. Strong decrease in TEA uptake; when associated with F-241. Strong decrease in TEA uptake; when associated with F-377. Strong decrease in TEA and metformin uptake and YES1-mediated tyrosine phosphorylation; when associated with F-241 and F-377.
377 Y→F: Slight decrease in TEA uptake. No change in tyrosine phosphorylation. Strong decrease in TEA uptake; when associated with F-362. Strong decrease in TEA and metformin uptake and YES1-mediated tyrosine phosphorylation; when associated with F-241 and F-362.
400 R → C: lower Vmax and reduced Ki value for TBA inhibition of MPP(+); lower transport efficiency (Vmax/Km) and clearance of cyclo(his-pro); no change in transport efficiency (Vmax/Km) and clearance of salsolinol; dbSNP:rs8177516
432 K → Q: lower Km value for MPP(+) and reduced Ki value for TBA inhibition of MPP; no change in transport efficiency (Vmax/Km) and clearance of cyclo(his-pro) and salsolinol; dbSNP:rs8177517
458 Y→F: No change in TEA uptake.
544 Y→F: No change in TEA uptake.

8et9A Cryo-em structure of the organic cation transporter 2 in complex with 1-methyl-4-phenylpyridinium (see paper)
24% identity, 53% coverage: 61:290/436 of query aligns to 156:375/517 of 8et9A

query
sites
8et9A

V

V

G

G

F

F

A

-

R

-

P

-

L

V

G

G

G

S

I

M

V

S

F

I

G

G

H

Y

I

I

G

A

D

D

R

R

I

F

G

G

R

R

K

K

K

L

S

C

L

L

I

L

I

V

T

T

L

I

L

L

M

I

M

N

G

A

V

I

V

S

T

G

V

V

C

L

I

M

G

A

L

V

L

A

P

P

T

N

Y

Y

A

T

Q

W

I

-

G

-

A

-

P

-

V

-

L

-

L

M

I

L

L

I

L

F

R

R

I

L

V

I

Q

Q

G

G

I

L

A

V

V

S

G

K

G

G

E

G

W
|
W

G

L

G

I

A

G

V

Y

L

T

M

L

A

P

G

T

E

E

H

F

A

V

P

G

K

L

G

E

R

Y

R

R

N

R

F

T

F

V

A

G

S

I

F

L

A

Y

Q
|
Q

L

M

G

A

S
x
F

P

S

A

V

G

G

-

L

L

L

I

V

L

L

S

A

L

G

L

V

A

A

F

Y

S

A

A

-

V

-

T

-

R

-

L

I

P

P

E

H

E

-

D

-

L

-

M

-

S

-

W

-

G

-

W

W

R

R

L

W

P

L

F

Q

L

L

A

A

S

V

S

T

L

L

L

P

L

N

L

F

V

F

G

F

L

L

A

L

I

Y

R

Y

L

W

G

C

V

I

N

P

E

E

S

S

P

P

E

R

F

W

L

L

A

I

S

S

R

Q

E

N

L

K

A

N

S

A

K

K

-

A

-

M

-

K

-

I

-

K

-

H

-

I

-

A

N

K

K

K

R

N

K

G

E

K

Q

K

A

L

P

P

V

K

M

S

E

E

V

K

L

L

R

N

T

P

A

S

W

F

R

L

P

D

L

L

L

V

L

R

C

T

-

P

-

Q

I

I

G

R

A

K

N

H

T

T

L

L

G

I

I

L

A

M

G

Y

V

N

Y

W

F

F

T

T

N

S

T

S

F

V

M

L

I

Y

A

Q

Y

G

T

L

T

I

Q

M

Q

H

L

M

E

G

L

I

P

A

R

G

S

G

L

N

I

I

L

Y

E

L

C

D

L

F

F

F

V

Y

V

S

A

A

I

L

I

V

Q

E

F

F

binding 1-methyl-4-phenylpyridin-1-ium: W216 (= W132), Q240 (= Q156), F243 (≠ S159)

Sites not aligning to the query:

binding 1-methyl-4-phenylpyridin-1-ium: 430

8sc2A Human oct1 bound to diltiazem in inward-open conformation (see paper)
27% identity, 41% coverage: 56:235/436 of query aligns to 143:292/453 of 8sc2A

query
sites
8sc2A

F

F

G

G

T

S

F

L

A

G

V

V

G

G

F

Y

F

F

A

A

R

-

P

-

L

-

G

-

I

-

V

-

F

-

G

-

H

-

I

-

G

-

D

D

R

R

I

F

G

G

R

R

K

K

K

L

S

C

L

L

I

L

I

G

T

T

L

V

L

L

M

V

M

N

G

A

V

V

V

S

T

G

V

V

C

L

I

M

G

A

L

F

L

S

P

P

T

N

Y

Y

A

M

Q

S

I

-

G

-

A

-

P

-

V

-

L

-

L

M

I

L

L

L

L

F

R

R

I

L

V

L

Q

Q

G

G

I

L

A

V

V

S

G

K

G

G

E

N

W
|
W

G

M

G

A

A

G

V

Y

L

T

M

L

A

I

G

T

E

E

H

F

A

V

P

G

K

S

G

G

R

S

R

R

N

R

F

T

F

V

A

A

S

I

F

M

A

Y

Q
|
Q

L

M

G

A

S
x
F

P

T

A

V

G

G

L

L

I

V

-

A

L

L

S

T

L

G

L

L

A

A

F

Y

S

A

A

-

V

-

T

-

R

-

L

L

P

P

E

H

E

-

D

-

L

-

M

-

S

-

W

-

G

-

W

W

R

R

L

W

P

L

F

Q

L

L

A

A

S

V

S

S

L

L

L

P

L

T

L

F

V

L

G

F

L

L

A

L

I

Y

R

Y

L

W

G

C

V

V

N

P

E

E

S

S

P

P

E

R

F

S

L

P

A

S

S

F

R

A

E

D

L

L

A

F

S

R

K

T

N

P

K

R

R

L

K

R

E

K

Q

R

A

T

P

F

V

I

M

L

E

M

V

Y

L

L

binding Diltiazem: W199 (= W132), Q223 (= Q156), F226 (≠ S159)

Sites not aligning to the query:

binding Diltiazem: 18, 293, 297, 385

P38695 Probable glucose transporter HXT5 from Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast) (see paper)
28% identity, 38% coverage: 68:232/436 of query aligns to 149:310/592 of P38695

query
sites
P38695

L

I

G

G

I

I

V

V

F

L

G

S

H

K

I

L

G

G

D

D

R

M

I

Y

G

G

R

R

K

K

K

-

S

-

L

-

I

-

T

-

L

-

M

-

M

I

G

G

V

L

V

M

T

T

V

V

C

V

I

V

G

I

L

Y

L

S

P

I

T

G

Y

I

A

I

Q

I

I

Q

G

I

A

A

A

S

A

I

P

D

-

K

-

W

V

Y

L

Q

L

Y

I

F

L

I

L

G

R

R

I

I

V

I

Q

S

G

G

I

L

A

G

V

V

G

G

E

I

W

T

G

V

G

L

A

A

V

P

L

M

M

L

A

I

G

S

E

E

H

V

A

S

P

P

K

K

G

Q

R

L

R

R

N

G

F

T

F

L

A

V

S

S

F

C

A

Y

Q

Q

L

L

G

M

S

I

P

T

A

F

G

G

L

I

I

F

L

L

S

G

L

Y

L

C

A

T

F

N

S

F

A

G

V

T

T

K

R

N

L

Y

P

S

E

N

E

-

D

-

L

-

M

-

S

S

W

V

G

Q

W

W

R

R

L

V

P

P

F

L

-

G

-

L

-

C

L

F

A

A

S

W

S

S

L

I

L

F

L

M

L

I

V

V

G

G

L

M

A

T

I

F

R

-

L

-

G

-

V

V

N

P

E

E

S

S

P

P

E

R

F

Y

L

L

-

V

-

E

-

V

-

G

-

K

-

I

-

E

A

A

S

K

R

R

E

S

L

L

A

A

S

R

K

A

N

N

K

K

R

T

K

T

E

E

Q

D

A

S

P

P

V

L

M

V

Sites not aligning to the query:

61 modified: Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)

Q9Y7Q9 Probable metabolite transporter C2H8.02 from Schizosaccharomyces pombe (strain 972 / ATCC 24843) (Fission yeast) (see paper)
25% identity, 35% coverage: 68:221/436 of query aligns to 98:259/583 of Q9Y7Q9

query
sites
Q9Y7Q9

L

M

G

G

G

Q

I

L

V

L

F

F

G

G

H

F

I

L

G

G

D

D

R

F

I

F

G

G

R

R

K

K

K

F

S

V

L

Y

I

G

I

K

T

E

L

M

M

V

G

I

V

I

V

A

T

T

V

I

C

L

I

I

G

I

L

C

L

L

P

P

T

D

Y

R

A

I

Q

P

I

T

G

P

A

T

A

A

A

K

P

M

V

M

L

W

L

L

I

F

L

A

L

F

R

R

I

V

V

M

Q

L

G

G

I

I

A

G

V

I

G

G

E

D

W

Y

G

P

G

M

A

S

V

A

L

S

M

I

A

T

G

S

E

E

H

Q

A

S

P

L

K

I

G

N

R

R

N

G

-

A

-

L

-

A

F

W

F

I

A

F

S

S

F

N

A

Q

Q

G

L

W

G

G

S

T

P

L

A

A

G

G

L

C

I

V

L

A

S

T

L

L

L

I

A

I

F

L

S

A

A

C

V

F

T

E

R

K

L

-

P

P

E

L

E

N

D

D

L

R

M

G

S

E

W

Y

G

T

-

K

-

L

-

N

-

G

-

V

W

W

R

R

L

I

P

Q

F

F

L

G

A

I

S

A

S

L

L

F

L

P

L

A

L

V

V

I

G

V

L

L

A

I

I

P

R

R

L

L

G

R

V

M

N

Q

E

E

S

S

P

E

E

Q

F

F

L

K

A

N

S

S

R

K

E

N

L

M

A

K

S

S

Sites not aligning to the query:

267 modified: Phosphoserine
269 modified: Phosphoserine
289 modified: Phosphoserine
290 modified: Phosphoserine
292 modified: Phosphoserine
330 modified: Phosphoserine

5eqiA Human glut1 in complex with cytochalasin b (see paper)
26% identity, 43% coverage: 49:236/436 of query aligns to 63:224/447 of 5eqiA

query
sites
5eqiA

L

I

F

F

S

S

T

V

M

G

A

G

A

M

F

I

G

G

T

S

F

F

A

S

V

V

G

G

F

L

F

F

A

V

R

-

P

-

L

-

G

-

I

-

V

-

F

-

G

-

H

-

I

-

G

-

D

N

R

R

I

F

G

G

R

R

K

R

K

N

S

S

L

M

I

-

T

-

L

-

L

L

M

M

G

N

V

L

T

A

V

F

C

V

I

S

G

A

L

V

L

L

P

M

T

G

Y

F

A

S

Q

K

I

L

G

G

A

K

A

S

A

F

P

E

V

-

L

M

L

L

I

I

L

L

L

G

R

R

I

F

V

I

Q

I

G

G

I

V

A

Y

V

C

G

G

G

L

E

T

W
x
T

G

G

G

F

A

V

V

P

L

M

M

Y

A

V

G

G

E

E

H

V

A

S

P

P

K

T

G

A

R

L

R

R

N

G

F

A

F

L

A

G

S

T

F

L

A

H

Q
|
Q

L

L

G

G

S
x
I

P

V

A

V

G

G

L

I

I

L

L

I

S

A

L

Q

L

V

A

-

F

F

S

G

A

L

V

D

T

S

R

I

L

M

P

G

E

N

E

K

D

D

L

L

M

-

S

-

W

W

G

-

W

-

R

-

L

-

P

P

F

L

L

L

A

L

S

S

S

I

L

I

L

F

L

I

-

P

-

A

L

L

V

L

G

Q

L

C

A

I

I

V

R

L

L

P

G

F

V

C

N

P

E

E

S

S

P

P

E

R

F

F

L

L

A

-

S

-

R

-

E

-

L

L

A

I

S

N

K

R

N

N

K

E

R

E

K

N

E

R

Q

A

A

K

P

S

V

V

M

L

E

K

V

K

L

L

R

R

binding Cytochalasin B: T129 (≠ W132), Q153 (= Q156), I156 (≠ S159)

Sites not aligning to the query:

binding Cytochalasin B: 274, 376, 380, 403, 404

5eqhA Human glut1 in complex with inhibitor (2~{s})-3-(2-bromophenyl)-2-[2- (4-methoxyphenyl)ethanoylamino]-~{n}-[(1~{s})-1- phenylethyl]propanamide (see paper)
26% identity, 43% coverage: 49:236/436 of query aligns to 63:224/447 of 5eqhA

query
sites
5eqhA

L

I

F

F

S

S

T

V

M

G

A

G

A

M

F

I

G

G

T
x
S

F

F

A

S

V

V

G

G

F

L

F

F

A

V

R

-

P

-

L

-

G

-

I

-

V

-

F

-

G

-

H

-

I

-

G

-

D

N

R

R

I

F

G

G

R

R

K

R

K

N

S

S

L

M

I

-

T

-

L

-

L

L

M

M

G

N

V

L

T

A

V

F

C

V

I

S

G

A

L

V

L

L

P

M

T

G

Y

F

A

S

Q

K

I

L

G

G

A

K

A

S

A

F

P

E

V

-

L

M

L

L

I

I

L

L

L

G

R

R

I

F

V

I

Q

I

G

G

I

V

A

Y

V

C

G

G

G

L

E

T

W
x
T

G

G

G

F

A

V

V

P

L

M

M

Y

A

V

G

G

E

E

H

V

A

S

P

P

K

T

G

A

R

L

R

R

N

G

F

A

F

L

A

G

S

T

F

L

A

H

Q

Q

L

L

G

G

S

I

P

V

A

V

G

G

L

I

I

L

L

I

S

A

L

Q

L

V

A

-

F

F

S

G

A

L

V

D

T

S

R

I

L

M

P

G

E

N

E

K

D

D

L

L

M

-

S

-

W

W

G

-

W

-

R

-

L

-

P

P

F

L

L

L

A

L

S

S

S

I

L

I

L

F

L

I

-

P

-

A

L

L

V

L

G

Q

L

C

A

I

I

V

R

L

L

P

G

F

V

C

N

P

E

E

S

S

P

P

E

R

F

F

L

L

A

-

S

-

R

-

E

-

L

L

A

I

S

N

K

R

N

N

K

E

R

E

K

N

E

R

Q

A

A

K

P

S

V

V

M

L

E

K

V

K

L

L

R

R

binding (2~{S})-3-(2-bromophenyl)-2-[2-(4-methoxyphenyl)ethanoylamino]-~{N}-[(1~{S})-1-phenylethyl]propanamide: S72 (≠ T58), T129 (≠ W132)

Sites not aligning to the query:

binding (2~{S})-3-(2-bromophenyl)-2-[2-(4-methoxyphenyl)ethanoylamino]-~{N}-[(1~{S})-1-phenylethyl]propanamide: 274, 371, 380, 400, 403, 404

5eqgA Human glut1 in complex with inhibitor (2~{s})-3-(4-fluorophenyl)-2-[2- (3-hydroxyphenyl)ethanoylamino]-~{n}-[(1~{s})-1- phenylethyl]propanamide (see paper)
26% identity, 43% coverage: 49:236/436 of query aligns to 63:224/447 of 5eqgA

query
sites
5eqgA

L

I

F

F

S

S

T

V

M

G

A

G

A

M

F

I

G

G

T

S

F

F

A

S

V

V

G

G

F

L

F

F

A

V

R

-

P

-

L

-

G

-

I

-

V

-

F

-

G

-

H

-

I

-

G

-

D

N

R

R

I

F

G

G

R

R

K

R

K

N

S

S

L

M

I

-

T

-

L

-

L

L

M

M

G

N

V

L

T

A

V

F

C

V

I

S

G

A

L

V

L

L

P

M

T

G

Y

F

A

S

Q

K

I

L

G

G

A

K

A

S

A

F

P

E

V

-

L

M

L

L

I

I

L

L

L

G

R

R

I

F

V

I

Q

I

G

G

I

V

A

Y

V

C

G

G

G

L

E

T

W
x
T

G

G

G

F

A

V

V

P

L

M

M

Y

A

V

G

G

E

E

H

V

A

S

P

P

K

T

G

A

R

L

R

R

N

G

F

A

F

L

A

G

S

T

F

L

A

H

Q

Q

L

L

G

G

S

I

P

V

A

V

G

G

L

I

I

L

L

I

S

A

L

Q

L

V

A

-

F

F

S

G

A

L

V

D

T

S

R

I

L

M

P

G

E

N

E

K

D

D

L

L

M

-

S

-

W

W

G

-

W

-

R

-

L

-

P

P

F

L

L

L

A

L

S

S

S

I

L

I

L

F

L

I

-

P

-

A

L

L

V

L

G

Q

L

C

A

I

I

V

R

L

L

P

G

F

V

C

N

P

E

E

S

S

P

P

E

R

F

F

L

L

A

-

S

-

R

-

E

-

L

L

A

I

S

N

K

R

N

N

K

E

R

E

K

N

E

R

Q

A

A

K

P

S

V

V

M

L

E

K

V

K

L

L

R

R

binding (2~{S})-3-(4-fluorophenyl)-2-[2-(3-hydroxyphenyl)ethanoylamino]-~{N}-[(1~{S})-1-phenylethyl]propanamide: T129 (≠ W132)

Sites not aligning to the query:

binding (2~{S})-3-(4-fluorophenyl)-2-[2-(3-hydroxyphenyl)ethanoylamino]-~{N}-[(1~{S})-1-phenylethyl]propanamide: 274, 380, 403, 404

8sc6A Human oct1 bound to thiamine in inward-open conformation (see paper)
28% identity, 25% coverage: 56:164/436 of query aligns to 143:231/447 of 8sc6A

query
sites
8sc6A

F

F

G

G

T

S

F

L

A

G

V

V

G

G

F

Y

F

F

A

A

R

-

P

-

L

-

G

-

I

-

V

-

F

-

G

-

H

-

I

-

G

-

D

D

R

R

I

F

G

G

R

R

K

K

K

L

S

C

L

L

I

L

I

G

T

T

L

V

L

L

M

V

M

N

G

A

V

V

V

S

T

G

V

V

C

L

I

M

G

A

L

F

L

S

P

P

T

N

Y

Y

A

M

Q

S

I

-

G

-

A

-

P

-

V

-

L

-

L

M

I

L

L

L

L

F

R

R

I

L

V

L

Q

Q

G

G

I

L

A

V

V

S

G

K

G

G

E

N

W

W

G

M

G

A

A

G

V

Y

L

T

M

L

A

I

G

T

E

E

H

F

A

V

P

G

K

S

G

G

R

S

R

R

N

R

F

T

F

V

A

A

S

I

F

M

A

Y

Q
|
Q

L

M

G

A

S
x
F

P

T

A

V

G

G

L

L

I

V

binding 3-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-5-(2-hydroxy-ethyl)-4-methyl-thiazol-3-ium: Q223 (= Q156), F226 (≠ S159)

Sites not aligning to the query:

binding 3-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-5-(2-hydroxy-ethyl)-4-methyl-thiazol-3-ium: 293, 294, 318, 378, 379

8sc3A Human oct1 bound to fenoterol in inward-open conformation (see paper)
28% identity, 25% coverage: 56:164/436 of query aligns to 143:231/445 of 8sc3A

query
sites
8sc3A

F

F

G

G

T

S

F

L

A

G

V

V

G

G

F

Y

F

F

A

A

R

-

P

-

L

-

G

-

I

-

V

-

F

-

G

-

H

-

I

-

G

-

D

D

R

R

I

F

G

G

R

R

K

K

K

L

S

C

L

L

I

L

I

G

T

T

L

V

L

L

M

V

M

N

G

A

V

V

V

S

T

G

V

V

C

L

I

M

G

A

L

F

L

S

P

P

T

N

Y

Y

A

M

Q

S

I

-

G

-

A

-

P

-

V

-

L

-

L

M

I

L

L

L

L

F

R

R

I

L

V

L

Q

Q

G

G

I

L

A

V

V

S

G

K

G

G

E

N

W
|
W

G
x
M

G

A

A

G

V

Y

L

T

M

L

A

I

G

T

E

E

H

F

A

V

P

G

K

S

G

G

R

S

R

R

N

R

F

T

F

V

A

A

S

I

F

M

A

Y

Q
|
Q

L

M

G

A

S
x
F

P

T

A

V

G

G

L

L

I

V

binding Fenoterol: W199 (= W132), M200 (≠ G133), Q223 (= Q156), F226 (≠ S159)

Sites not aligning to the query:

binding Fenoterol: 284, 291, 376, 380

P11166 Solute carrier family 2, facilitated glucose transporter member 1; Glucose transporter type 1, erythrocyte/brain; GLUT-1; HepG2 glucose transporter from Homo sapiens (Human) (see 23 papers)
26% identity, 43% coverage: 49:236/436 of query aligns to 71:232/492 of P11166

query
sites
P11166

L

I

F

F

S

S

T

V

M

G

A

G

A
x
M

F

I

G

G

T

S

F

F

A

S

V

V

G

G

F

L

F

F

A

V

R

-

P

-

L

-

G

-

I

-

V

-

F

-

G

-

H

-

I

-

G

-

D

N

R

R

I

F

G
|
G

R

R

K

R

K

N

S

S

L

M

I

-

T

-

L

-

L

L

M

M

G

N

V

L

T

A

V

F

C

V

I

S

G

A

L

V

L

L

P

M

T

G

Y

F

A

S

Q

K

I

L

G

G

A

K

A

S

A

F

P

E

V

-

L

M

L

L

I

I

L

L

L

G

R
|
R

I

F

V

I

Q

I

G
|
G

I

V

A

Y

V

C

G

G

G

L

E

T

W
x
T

G

G

G

F

A

V

V

P

L

M

M

Y

A

V

G

G

E

E

H

V

A

S

P
|
P

K

T

G

A

R

L

R
|
R

N

G

F

A

F

L

A

G

S

T

F

L

A

H

Q

Q

L

L

G

G

S

I

P

V

A

V

G

G

L

I

I
x
L

L

I

S

A

L

Q

L

V

A

-

F

F

S

G

A

L

V

D

T

S

R

I

L

M

P

G

E

N

E

K

D

D

L

L

M

-

S

-

W

W

G

-

W

-

R

-

L

-

P

P

F

L

L

L

A

L

S

S

S
x
I

L

I

L

F

L

I

-

P

-

A

L

L

V

L

G

Q

L

C

A

I

I

V

R
x
L

L
x
P

G

F

V

C

N

P

E

E

S

S

P

P

E
x
R

F

F

L

L

A

-

S

-

R

-

E

-

L

L

A

I

S

N

K
x
R

N

N

K

E

R

E

K

N

E
x
R

Q

A

A

K

P
x
S

V

V

M

L

E

K

V

K

L

L

R
|
R

M77 (≠ A55) to T: in EIG12; decreased glucose transport; dbSNP:rs1187210267
G91 (= G81) to D: in GLUT1DS1; significantly decreases the transport of 3-O-methyl-D-glucose; dbSNP:rs80359814
R126 (= R121) to C: in GLUT1DS1, GLUT1DS2 and DYT9; reduced transporter activity; dbSNP:rs80359818; to H: in GLUT1DS1; significantly decreases the transport of 3-O-methyl-D-glucose and dehydroascorbic acid; 57% of wild-type glucose uptake activity; dbSNP:rs80359816
G130 (= G125) to S: in GLUT1DS1; 75% of wild-type glucose uptake activity; dbSNP:rs80359819
T137 (≠ W132) binding
P149 (= P144) to A: in EIG12; uncertain significance
R153 (= R148) to C: in GLUT1DS1; 44% of wild-type glucose uptake activity
L169 (≠ I164) natural variant: Missing (in GLUT1DS1; 48% of wild-type glucose uptake activity; dbSNP:rs80359832)
I192 (≠ S194) mutation to C: Strongly decreases glucose transport.
L204 (≠ R204) mutation to C: Abolishes glucose transport.
P205 (≠ L205) mutation to C: Abolishes glucose transport.
R212 (≠ E212) to C: in GLUT1DS1 and DYT9; dbSNP:rs387907312
R218 (≠ K222) to S: in EIG12; decreased glucose transport
R223 (≠ E227) to P: in EIG12; mild phenotype; reduced transporter activity; impaired phosphorylation by PKC; dbSNP:rs397514564; to Q: in EIG12; uncertain significance; no effect on glucose transport; impaired phosphorylation by PKC; dbSNP:rs397514564; to W: in GLUT1DS1; impaired phosphorylation by PKC; dbSNP:rs796053248
S226 (≠ P230) modified: Phosphoserine; by PKC/PRKCB; mutation to A: Abolishes phosphorylation by PKA, leading to impaired response to TPA.
R232 (= R236) to C: in EIG12; the mutant protein is expressed at the cell surface but has mildly decreased glucose uptake (70%) compared to wild-type; dbSNP:rs387907313

Sites not aligning to the query:

34 N → S: in GLUT1DS1; 55% of wild-type glucose uptake activity; dbSNP:rs80359812
45 modified: carbohydrate, N-linked (GlcNAc...) asparagine; N→T: Loss of glycosylation site.
51 R → H: in EIG12; uncertain significance; dbSNP:rs201815571
60 T → M: in EIG12; uncertain significance; decreased glucose transport; dbSNP:rs142986731
243 E → V: in EIG12; decreased glucose transport
275 A → T: in GLUT1DS2; the mutation decreases glucose transport but does not affect cation permeability; dbSNP:rs121909740
282 binding
282:285 natural variant: Missing (in GLUT1DS2; accompanied by hemolytic anemia and altered erythrocyte ion concentrations; the mutation decreases glucose transport and causes a cation leak that alteres intracellular concentrations of sodium potassium and calcium)
286 G → D: in SDCHCN; no effect on protein abundance; no effect on localization to the plasma membrane; loss of D-glucose transporter activity; increased cation leakage; dbSNP:rs864309514
295 T → M: in GLUT1DS1; 75% of wild-type glucose uptake activity; dbSNP:rs80359823
303 V → L: found in a patient with GLUT1 deficiency syndrome; dbSNP:rs1205631854
314 G → S: in GLUT1DS2; the mutation decreases glucose transport but does not affect cation permeability; dbSNP:rs121909739
324 S → L: in GLUT1DS2; mild phenotype; reduced transporter activity; dbSNP:rs796053253
329 E → Q: in GLUT1DS1; stabilizes the inward-open conformation
333 R → Q: in GLUT1DS1 and GLUT1DS2; dbSNP:rs1553155986; R → W: in GLUT1DS1; 43% of wild-type glucose uptake activity; dbSNP:rs80359825
340 G→C: Strongly decreases glucose transport.
388 binding
411 Not glycosylated; binding ; N → S: in EIG12; decreased glucose transport; dbSNP:rs398123069
435 natural variant: Missing (in SDCHCN; no effect on protein abundance; no effect on localization to the plasma membrane; loss of D-glucose transporter activity; increased cation leakage)
458 R → W: in EIG12; decreased glucose transport; dbSNP:rs13306758
485 P → L: in GLUT1DS1; creates a dileucine internalization motif that promotes recruitment of clathrin and mislocalization of the protein to endocytic compartments

Query Sequence

>PfGW456L13_2351 FitnessBrowser__pseudo13_GW456_L13:PfGW456L13_2351
MKPQASSQPRRAAAAAFIGTMIEWYDFYIYATAAALVFGALFFPSDDKLFSTMAAFGTFA
VGFFARPLGGIVFGHIGDRIGRKKSLIITLLMMGVVTVCIGLLPTYAQIGAAAPVLLILL
RIVQGIAVGGEWGGAVLMAGEHAPKGRRNFFASFAQLGSPAGLILSLLAFSAVTRLPEED
LMSWGWRLPFLASSLLLLVGLAIRLGVNESPEFLASRELASKNKRKEQAPVMEVLRTAWR
PLLLCIGANTLGIAGVYFTNTFMIAYTTQQLELPRSLILECLFVVAIIQFCIQPLAAWVA
EKIGATRFLCLVSLLAMASPYPMFVLVSSAQAPLIILGIALAVVCMASFYAVIAGYVSGM
FETRVRYTAISLAYQICGAVAGGLTPLIGTLLAHRFVGQWWPMAVFYSLIAATSLLCVLS
LARRHASAERLELAKA

Or try a new SitesBLAST search

SitesBLAST's Database

SitesBLAST's database includes (1) SwissProt entries with experimentally-supported functional features; and (2) protein structures with bound ligands, from the BioLip database.

by Morgan Price, Arkin group
Lawrence Berkeley National Laboratory